Posts tagged ‘Merck’
March 11th, 2011
At Icarus Consultants we do projects on a wide range of therapeutic areas, although we are perhaps most well known for our expertise in oncology, hematology and targeted therapies.
Pieter Droppert who writes the Biotech Strategy Blog has a series of posts on the osteoporosis market. The latest discusses targeting sclerostin. Other posts discuss emerging drugs in development, and cathepsin-K inhibitors.
While at Quintiles, Pieter worked on the phase III clinical trials for risedronate. However, his interest in bone metabolism goes back to a review on “The Effects of Microgravity on the Skeletal System” that he wrote while completing his masters degree in physiology.
If you are interested in bringing new products to market for osteoporosis or wish to discuss the competitive dynamics within this market, please contact us.
February 11th, 2011
Following on from news about the emerging competitive landscape in osteoporosis, Pieter Droppert on the Biotech Strategy Blog considers in more detail Merck’s odanacatib, currently in phase III clinical trials.
Odanacatib is first of a new class of drugs for the treatment of osteoporosis known as cathepsin K inhibitors (CAT-K). You can read more on Biotech Strategy Blog about this new product, its mechanism of action and the marketing strategy associated with its development.
January 18th, 2011
Published by Sally Church on Pharma Strategy Blog